Back to Awarded Treatment Trials
Awarded Trial: 00-133
Grant ID
00-133
Illness
Schizophrenia
Primary Drug/Intervention
Risperidone
Primary Dosage
(discharge rate)
Secondary Drug Intervention
Olanzapine
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Sheitman
Sample Size
85
Duration of Study Period for Each Subject
6.9 days (Risperidone), 7 days (Olanzapine), 10-20 days
Outcome Measurements
PANSS, duration of hospitalization (number of days to discharge), GAF, Chi Square
Results
The authors compared the efficacy of risperidone and olanzapine in hospitalized acutely psychotic patients. Eighty five patients were enrolled and duration of hospitalization was the principal outcome measurement. There was no difference between the two medications on this measure.
Publication
Kraus JE, Sheitman BB, Cook A, Reviere R, Lieberman JA. Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. J Clin Psychiatry. 2005 Dec;66(12):1564-8.
Link
http://www.ncbi.nlm.nih.gov/pubmed/16401158
PI Name
Brian Sheitman
Degree
MD
Center
Department of Psychiatry
Institution
The University of North Carolina at Chapel Hill
Address
CB # 7160
City or Town
Chapel Hill
State or Province
NC
Zip or Postal Code
27599
Country
USA
Email Address
brian.sheitman@ncmail.net